Drug – bio-affecting and body treating compositions – In vivo diagnosis or in vivo testing – Testing efficacy or toxicity of a compound or composition
Reexamination Certificate
2005-11-08
2005-11-08
Falk, Anne-Marie (Department: 1632)
Drug, bio-affecting and body treating compositions
In vivo diagnosis or in vivo testing
Testing efficacy or toxicity of a compound or composition
C424S009100, C435S006120, C435S007100, C435S007200, C435S007210, C435S455000, C800S003000, C800S008000, C800S013000, C800S014000, C800S018000
Reexamination Certificate
active
06962688
ABSTRACT:
Methods for regulation of lipid and cholesterol uptake are described which are based on regulation of the expression or function of the SR-BI HDL receptor. The examples demonstrate that estrogen dramatically downregulates SR-BI under conditions of tremendous upregulation of the LDL-receptor. The examples also demonstrate the upregulation of SR-BI in rat adrenal membranes and other non-placental steroidogenic tissues from animals treated with estrogen, but not in other non-placental non-steroidogenic tissues, including lung, liver, and skin. Examples further demonstrate the uptake of fluorescently labeled HDL into the liver cells of animal, which does not occur when the animals are treated with estrogen. Examples also demonstrate the in vivo effects of SR-BI expression on HDL metabolism, in mice transiently overexpressing hepatic SR-BI following recombinant adenovirus infection. Overexpression of the SR-BI in the hepatic tissue caused a dramatic decrease in cholesterol blood levels. These results demonstrate that modulation of SR-BI levels, either directly or indirectly, can be used to modulate levels of cholesterol in the blood.
REFERENCES:
patent: 5211947 (1993-05-01), Brannan et al.
patent: 5746223 (1998-05-01), Williams
patent: 5925333 (1999-07-01), Krieger et al.
patent: WO 90/05748 (1990-05-01), None
patent: WO 93/012860 (1993-01-01), None
patent: WO 93/19166 (1993-09-01), None
patent: WO 96/00288 (1996-01-01), None
Campbell and Wilmut, Totipotency or multipotentiality of cultured cells: applications and progress, Theriogenology, 47:63-72, Jan. 1997.
Krieger, The “best” of cholesterols, the “worst” of cholesterols: a tale of two receptors, Proc. Natl. Acad. Sci. USA, 95:4077-4080, Apr. 1998.
Wang et al., Liver-specific overexpression of scavenger receptor Bl decreases lelvels of very low density lipoprotein ApoB, low density lipoprotein ApoB, and high density lipoprotein in transgenic mice, J. Biol. Chem., 273(49):32920-32926, Dec. 1998.
Arai et al., Decreased athersclerosis in heterozygous low density lipoprotein receptor-deficient mice expressing the scavenger receptor Bl transgene, J. Biol. Chem., 274(4):2366-2371, Jan. 1999.
Wall, Transgenic livestock: progress and prospects for the future, Theriogenology, 45:57-68, 1996.
Robl and Heideman, Production of transgenic rats and rabbits, Transgenic animal technology, Pinkert, CA (ed), Academic Press, Inc., San Diego, CA, p. 266, 1994.
Mullins et al., Fulminant hypertension in transgenic rats harbouring the mouse Ren-2 gene, Nature, 344:541-544, Apr. 1990.
Hammer et al., Spontaneous inflammatory disease in transgenic rats expressing HLA-B27 and human beta-2m: an animal model of HLA-B27-associated human disorders, Cell, 63:1099-1112, Nov. 1990.
Mullins et al., Expression of the DBA/2J Ren-2 gene in the adrenal gland of transgenic mice, EMBO J., 8(13):4065-4072, Dec. 1989.
Taurog et al., HLA-B27 in inbred and non-inbred transgenic mice: cell surface expression and recognition as an alloantigen in the absence of human beta-2-microglobulin, J. Immunol., 141(11):4020-4023, Dec. 1988.
Landschulz et al., Regulation of scavenger receptor, class B, type I, a high ensity lipoprotein receptor, in liver and steroidogenic tissues of the rat, J. Clin. Invest., 98(4):984-995, Aug. 1996.
Abrams, et al., “Macrophages in Drosophila embryos and L2 cells exhibit scavenger receptor-mediated endocytosis,”Proc Natl Acad Sci U S A.89(21):10375-9 (1992).
Abumrad, et al., “Cloning of a rat adipocyte membrane protein implicated in binding or transport of long-chain fatty acids that is induced during preadipocyte differentiation. Homology with human CD36,”J Biol Chem.268(24):17665-8 (1993).
Acton, et al., “Expression cloning of SR-BI, a CD36-related class B scavenger receptor,”J Biol Chem.269(33):21003-9 (1994).
Acton, et al., “Identification of scavenger receptor SR-BI as a high density lipoprotein receptor,”Science.271(5248):518-20 (1996).
Acton, et al., “The collagenous domains of macrophage scavenger receptors and complement component C1q mediate their similar, but not identical, binding specificities for polyanionic ligands,”J. Biol. Chem.268:3530-3537 (1993).
Agrawal, et al., “Oligodeoxynucleoside phosphoramidates and phosphorothioates as inhibitors of human immunodeficiency virus,”Proc Natl Acad Sci U S A.85(19):7079-83 (1988).
Anderson & Dietschy, “Kinetic Parameters of the Lipoprotein Transport Systems in the Adrenal Gland of the Rat Determined in Vivo,”J. Biol. Chem.256:7362-7370 (1981).
Arai, et al., “Multiple receptors for the modified low density lipoproteins in mouse peritoneal macrophages: different uptake mechanisms for acetylated and oxidized low density lipoproteins,”Biochem Biophys Res Commun.159(3):1375-82 (1989).
Aruffo & Seed, “Molecular cloning of CD28 cDNA by a high-efficiency COS cell expression system,”Proc. Natl. Acad. Sci. USA84:8573-77 (1987).
Asch, et al., “Isolation of the thrombospondin membrane receptor,”J Clin Invest.79(4):1054-61 (1987).
Ashkenas, et al., “Structures and high and low affinity ligand binding properties of murine type I and type II macrophage scavenger receptors,”J Lipid Res.34(6):983-1000 (1993).
Askew, et al., “Molecular Recognition with Convergent Functional Groups, Synthetic and Structural Studies with a Model Receptor for Nucleic Acid Components,”J. Am. Chem. Soc.111:1082-1090 (1989).
Azhar, et al. “Uptake and utilization of lipoprotein cholesteryl esters by rat granulosa cells,”Biochim. Biophys. Acta1047, 148-169 (1990).
Baldini, et al., “Cloning of a Rab3 Isotype Predominately Expressed in Adipocytes,”Proc. Natl. Acad. Sci. U.S.A.89:5049-5052 (1992).
Basu, et al., “Independent Pathways for Secretion of Cholesterol and Apolipoprotein E by Macrophages,”Science219:871-873 (1983).
Bickel, et al., “Rabbit Aortic Smooth Muscle Cells Express Inducible Macrophage Scavenger Receptor Messenger RNA that is Absent from Endothelial Cells,”J. Clin. Invest.90:1450-1457 (1992).
Blume, et al., “Truple Helix Formation by Purine-rich Oligonucleotides Targeted to the Human Dihydrofolate Reductase Promoter,”Nucl. Acids Res.20:1777-1784 (1992).
Brown & Goldstein, “Lipoprotein Metabolism In The Macrophage: Implications for Cholesterol Deposition in Atherosclerosis,”Annu. Rev. Biochem.52:223-261 (1983).
Calvo & Vega, “Identification, Primary Structure, and Distribution of CLA-1, a Novel Member of the CD36/LIMPII Gene Family,”J. Biol. Chem.268:18929:18935 (1993).
Charron, et al., “A Glucose Transport Protein Expressed Predominately in Insulin-responsive Tissues,”Proc. Natl. Acad. Sci. U.S.A.86:2535-2539 (1989).
Chen, et al., “NPXY, a Sequence Often Found in Cytoplasmic Tails, Is Required for Coated Pit-mediated Internalization of the Low Density Lipoprotein Receptor,”J. Biol. Chem.265(6):3116-3123 (1990).
Chung, et al., “Single vertical Spin Density Gradient Ultracentrifugation,” inMethods of Enzymology,Ed. J.P. Segrest and J.J. Albers (Academic Press, Inc. Orlando, FL 1986) vol. 128, pp. 181-209.
Clackson, et al., “Making Antibody Fragments Using Phage Display Libraries,”Nature352:624-628 (1991).
Cooney, et al., “Site-Specific Oligonucleotide Binding Represses Transcription of the Human c-myc Gene in Vitro,”Science241:456-459 (1988).
Crooke, “Progress Toward Oligonucleotide Therapeutics: Pharmacodynamic Properties,”FASEB J.7:533-539 (1993).
Cullen, “Guide to Molecular Cloning Techniques: Use of Eukaryotic Expression Technology in the Functional Analysis of Cloned Genes,”Methods in Enzymology152:684-704 (1987).
Daugherty, et al., “Polymerase Chain Reaction the Cloning, CDR-grafting, and Rapid Expression of a Murine Monoclonal Antibody Directed Against the CD18 Component of Leukocyte integrins,”Nucleic
Kozarsky Karen
Krieger Monty
Rigotti Attilio
Falk Anne-Marie
Massachusetts Institute of Technology
Pabst Patent Group LLP
Trustees of the University of Pennsylvania
LandOfFree
Methods for modulation of cholesterol transport does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for modulation of cholesterol transport, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for modulation of cholesterol transport will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3504180